Graticule logo

Graticule

Real-world data sourcing and evidence generation for clinical research, rare diseases, and global clinical trials.

Visit website

Overview

Graticule is a global research network operator and evidence generator that combines advanced real-world data (RWD) solutions with research networks to accelerate innovation for life science companies and health systems. Founded in 2019, Graticule helps clients navigate complex challenges in global data sourcing, research planning, and study execution — with a particular specialization in rare diseases, long-term follow-up (LTFU) studies, safety surveillance, and payer dossiers. By collaborating with health systems, hospitals, and data aggregators worldwide, Graticule enables life science leaders to harness the power of EHR data — including clinical notes, radiology reports, and ex-US data — to generate impactful real-world evidence and position products for commercial success.

Graticule serves both life science industry clients and health system and hospital partners across the US, EU, and APAC regions. For health systems, partnering with Graticule provides access to a global research network, resources for quality evidence generation, and opportunities to connect patients with new treatment options for improved outcomes.

Core Product Solutions

  • Study Source: Global real-world data sourcing, feasibility assessments, and integrated evidence planning. Helps clients understand research goals, expedite timelines, and map available data options to global research objectives.
  • Episcope: Agile, end-to-end planning and management of global real-world evidence studies, supporting resource flexibility and enhancing agility to meet evidence goals and shifting market conditions.
  • CLEHR: An eSourced, open-standard EHR-to-Sponsor digital network that automates data acquisition at scale, eliminates complexity at sites, enriches data sets, and ensures accuracy. Recently extended to process and de-identify PDFs.
  • Patient Finder: Precision patient screening logic and clinical decision support to identify and recruit eligible patients for studies and trials.

Real-World Evidence and Clinical Capabilities

  • Data licensing and global network building
  • Data feasibility and landscaping
  • Insights from EHR data, including both structured and unstructured sources
  • Clinical development support
  • Study planning and end-to-end execution
  • eSourcing for clinical data
  • Patient identification and clinical trial recruitment

Global Network and Partnerships

  • Graticule operates a growing global network of US and EU health systems and member hospitals.
  • Strategic partnerships include leading consultants in the health space, health systems across North America, Europe, and Asia-Pacific, and AI and data innovator partners.
  • Data and analytics partnerships bolster Graticule's ability to address unique client challenges at scale.

Leadership and Team

  • Dan Poscover, CEO and Co-Founder: A strategic advisor to life science companies, medical device organizations, and health systems; previously EVP of Strategy and Partnering at PatientsLikeMe.
  • Dan Housman, CTO and Co-Founder: An entrepreneur with expertise in using patient data to transform research and care delivery; leads development of Graticule's data and analytics solutions.
  • Kyle Conley, VP of Operations and Compliance: Expert in regulatory and quality systems, change management, performance management, and compliance.
  • Yuval Koren, VP of Engineering and Data Science: A Silicon Valley technologist and system architect with deep expertise in distributed systems, data engineering, and production machine learning.
  • The broader team includes data scientists, epidemiologists, clinical researchers, and software developers.

Graticule's fit-for-purpose approach bridges the data-to-study gap by overcoming long-standing barriers in accessing hard-to-reach global patient data — including remote, restricted, or unstructured sources — enabling life science companies to turn research concepts into impactful evidence and drive adoption of new clinical practices.